Faecal microbiota transplants have attracted considerable attention as a potential treatment for inflammatory bowel disease, driven by their dramatic success in recurrent Clostridioides difficile infection. Many patients with Crohn’s disease or ulcerative colitis wonder whether FMT could offer relief from their symptoms or reduce inflammation. The reality is more complex: whilst early research shows promise in specific contexts, FMT is not yet a proven therapy for IBD and outcomes vary widely.
What is faecal microbiota transplant?
Faecal microbiota transplant involves transferring processed stool from a healthy donor into the gastrointestinal tract of a recipient. The aim is to restore a balanced and diverse gut microbiome, the community of bacteria and other microorganisms living in the intestines. FMT can be delivered via colonoscopy, enema, or oral capsules containing freeze-dried material.
The procedure has been used successfully for years to treat recurrent C. difficile infection, where the gut microbiome is severely disrupted. In this setting, FMT is highly effective because it directly restores the microbial balance needed to suppress the infection. The question is whether this same principle applies to IBD, a chronic inflammatory condition with more complex underlying mechanisms.
Why the interest in FMT for IBD?
The gut microbiome plays a central role in IBD. People with Crohn’s disease and ulcerative colitis typically have reduced microbial diversity, lower levels of beneficial bacteria that produce short-chain fatty acids (molecules that help regulate inflammation and support the gut lining), and an overrepresentation of certain pro-inflammatory bacterial groups. This imbalance, known as dysbiosis, contributes to immune system activation and ongoing inflammation.
Because FMT can theoretically reset the microbiome, researchers have explored whether it might reduce inflammation or induce remission. However, IBD is driven by a combination of genetic susceptibility, immune dysregulation, environmental factors and microbial disturbance, making it far more complex than a purely microbiome-driven condition.
Evidence in ulcerative colitis
Most FMT research in IBD has focused on ulcerative colitis, and results have been mixed. Several randomised controlled trials have shown that FMT can induce clinical remission in a subset of patients with active disease, typically around 20 to 30 per cent, compared to 10 to 15 per cent with placebo. These figures suggest potential benefit, but also highlight that the majority of patients do not respond.
One challenge is variability. Response rates differ depending on the donor, the method of delivery, the frequency of administration and the characteristics of the recipient. Some studies have used single infusions, whilst others have employed multiple doses over weeks. There is no standardised protocol, and it is not yet clear which patients are most likely to benefit.
Importantly, even when FMT does induce remission, the effect may not be durable. Maintaining remission often requires repeated treatments, and the long-term safety and practicality of ongoing FMT are still being evaluated.
Evidence in Crohn’s disease
The evidence for FMT in Crohn’s disease is weaker than in ulcerative colitis. Crohn’s can affect any part of the digestive tract, often involves transmural inflammation (inflammation extending through the full thickness of the bowel wall) and is associated with complications such as strictures and fistulas. These features make it less amenable to a microbiome-based intervention.
Small studies have reported some clinical improvement in individual patients, but larger trials have not demonstrated consistent benefit. There is currently insufficient evidence to recommend FMT as a treatment for Crohn’s disease outside of research settings.
Mechanisms and limitations
FMT works best when the primary problem is microbial, as in C. difficile infection. In IBD, the relationship between the microbiome and inflammation is bidirectional: dysbiosis can drive inflammation, but inflammation also disrupts the microbiome. This creates a feedback loop that may limit the effectiveness of FMT.
Even when FMT successfully transfers donor bacteria, the recipient’s immune system, genetics and environmental factors continue to exert pressure on the microbiome. Without addressing these underlying drivers, the transplanted microbiota may not engraft long term, or the dysbiosis may return.
Another limitation is donor selection. Not all donors are equally effective, and the reasons for this variability are not fully understood. Some research suggests that specific bacterial strains or combinations are more beneficial, but identifying and standardising these remains a challenge.
Safety considerations
FMT is generally considered safe in the short term when rigorous donor screening is performed. Donors are tested for infectious diseases, and stool samples are screened for pathogens. However, there is a theoretical risk of transferring unknown or emerging infections, and rare serious adverse events have been reported.
Longer-term safety data in IBD are limited. There are concerns about the potential for FMT to trigger immune-related events or alter metabolic pathways in unintended ways. As with any emerging therapy, caution is warranted until more evidence is available.
Where FMT stands now
FMT is not currently a standard treatment for IBD. It is not recommended in clinical guidelines and is not widely available outside of clinical trials or specialist centres. Patients interested in FMT should discuss it with their gastroenterologist and consider whether enrolment in a research study is appropriate.
The therapy may hold promise for a subset of patients with ulcerative colitis, particularly those who have not responded to conventional treatments, but it is not a universal solution and does not replace established therapies such as biologics, immunomodulators or corticosteroids.
Research is ongoing to refine protocols, identify predictors of response and explore the use of defined microbial consortia rather than whole stool transplants.
Practical takeaways
- FMT has shown some benefit in ulcerative colitis in research settings, but the majority of patients do not achieve remission.
- Evidence for FMT in Crohn’s disease is limited and does not currently support its use as a treatment.
- FMT is not a replacement for conventional IBD therapies and should only be considered in consultation with a gastroenterologist.
- Donor variability and lack of standardised protocols mean outcomes are unpredictable.
- Long-term safety and durability of response remain areas of active investigation.
- Patients interested in FMT should seek information about clinical trials rather than pursuing unregulated options.
Conclusion
Faecal microbiota transplant is an intriguing and biologically plausible intervention for IBD, particularly ulcerative colitis, but it is not yet ready for routine clinical use. Whilst early studies suggest modest benefit in a minority of patients, the evidence does not support the enthusiasm sometimes seen in media coverage or online discussions. More research is needed to understand who might benefit, how to optimise delivery and what the long-term risks and benefits are. For now, FMT remains a promising area of investigation rather than a proven therapy.
References
- Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4
- Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321(2):156-164. doi:10.1001/jama.2018.20046
- Sood A, Mahajan R, Singh A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13(10):1311-1317. doi:10.1093/ecco-jcc/jjz060
- Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome. 2020;8(1):12. doi:10.1186/s40168-020-0792-5
- Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65(11):1906-1915. doi:10.1136/gutjnl-2016-312297
- Qazi T, Amaratunga T, Barnes EL, et al. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis. Gut Microbes. 2017;8(6):574-588. doi:10.1080/19490976.2017.1353848
- Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23(10):1702-1709. doi:10.1097/MIB.0000000000001228
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.